Published in J Clin Oncol on February 01, 1997
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood (2010) 2.45
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A (2003) 2.32
History of the Baylor Charles A. Sammons Cancer Center. Proc (Bayl Univ Med Cent) (2003) 2.15
CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A (1999) 1.93
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med (2004) 1.83
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant (2007) 1.74
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia (2011) 1.64
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer (2010) 1.62
Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant (2013) 1.62
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res (2014) 1.58
Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood (2015) 1.57
Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A (2010) 1.56
Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood (2007) 1.54
Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2010) 1.53
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 1.39
Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev (2010) 1.28
Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant (2009) 1.27
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. J Cell Mol Med (2008) 1.27
HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant (2013) 1.17
T cell receptor gene therapy for cancer. Hum Gene Ther (2009) 1.17
Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15
Relapse after allogeneic stem cell transplantation. Expert Rev Hematol (2010) 1.14
Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant (2015) 1.14
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant (2013) 1.13
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant (2008) 1.13
Mesenchymal stromal cells: a new tool against graft-versus-host disease? Biol Blood Marrow Transplant (2011) 1.11
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res (2010) 1.09
Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A (2003) 1.08
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res (2008) 1.08
Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol (2008) 1.07
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 1.06
Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood (2007) 1.06
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res (2010) 1.04
Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res (2008) 1.02
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant (2011) 1.02
Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol (2008) 1.01
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2009) 1.01
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res (2002) 0.98
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest (2016) 0.96
Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transplant (2015) 0.96
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 0.96
Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2012) 0.95
Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol (2002) 0.94
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur J Nucl Med Mol Imaging (2006) 0.94
Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci U S A (2008) 0.94
DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant (2014) 0.93
Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant (2015) 0.93
A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant (2014) 0.93
T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A (1998) 0.92
Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunology (2014) 0.91
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther (2010) 0.91
Antiviral T-cell therapy. Immunol Rev (2014) 0.91
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood (2012) 0.90
Adoptive cell therapies for glioblastoma. Front Oncol (2013) 0.90
Inference for current leukemia free survival. Lifetime Data Anal (2008) 0.90
Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica (2012) 0.90
Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am (2010) 0.90
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin Immunol (2010) 0.89
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant (2008) 0.89
Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol (2004) 0.89
Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol (2009) 0.88
Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J (2011) 0.88
Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest (1997) 0.87
Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter (2013) 0.87
Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia (2014) 0.86
A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 0.86
Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther (2010) 0.85
The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer (2014) 0.85
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies. Haematologica (2010) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Immunotherapy of childhood cancer: from biologic understanding to clinical application. Curr Opin Pediatr (2010) 0.84
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years. Bone Marrow Transplant (2015) 0.84
Immunotherapy for pediatric leukemia. Front Oncol (2013) 0.84
Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood (2011) 0.84
Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol (2004) 0.83
Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia (2011) 0.82
BCR-ABL1 transcripts (MR(4.5)) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia. Korean J Intern Med (2016) 0.82
Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. J Hematol Oncol (2009) 0.82
Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol (2007) 0.82
Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells. PLoS One (2013) 0.81
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. Biol Blood Marrow Transplant (2014) 0.81
A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice. Biomed Res Int (2013) 0.81
Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant (2014) 0.81
High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biol Blood Marrow Transplant (2008) 0.81
CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica (2010) 0.81
New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT. Bone Marrow Transplant (2015) 0.80
Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. Haematologica (2016) 0.80
Progress in the development of a therapeutic vaccine for breast cancer. Breast Cancer (Dove Med Press) (2010) 0.80
Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am (2011) 0.80
Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin Dev Immunol (2010) 0.80
High-resolution conformation of gramicidin A in a lipid bilayer by solid-state NMR. Science (1993) 5.33
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
The P53 pathway: what questions remain to be explored? Cell Death Differ (2006) 4.91
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med (1988) 3.62
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood (2001) 3.32
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol (1998) 3.06
Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med (1993) 2.85
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol (2001) 2.69
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia (2002) 2.68
The need for liver transplantation: a nationwide estimate based on consensus review. Lancet (1995) 2.58
Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem (2000) 2.54
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2008) 2.43
ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion (1999) 2.35
Improved survival for patients with acute myelogenous leukemia. J Clin Oncol (1995) 2.30
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells. J Virol (1989) 2.28
Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis (1999) 2.28
Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging (2001) 2.20
Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield. Transfusion (1997) 2.17
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol (1993) 2.11
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils. J Cell Biol (1995) 2.11
Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant (2008) 2.10
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther (2008) 2.07
Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology (2007) 2.05
Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation (1991) 2.04
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 2.04
Allogeneic blood stem cell transplantation: considerations for donors. Blood (1997) 2.03
Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices. J Cell Biol (1994) 2.03
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2001) 2.00
Hemorrhage in lesions caused by cowpox virus is induced by a viral protein that is related to plasma protein inhibitors of serine proteases. Proc Natl Acad Sci U S A (1986) 1.85
Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol (1994) 1.85
Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet (1991) 1.84
Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci U S A (2001) 1.84
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol (2001) 1.79
Intracranial hemorrhage after stenting and angioplasty of extracranial carotid stenosis. AJNR Am J Neuroradiol (2001) 1.78
Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg (1993) 1.77
Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol (2001) 1.76
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke (1999) 1.71
Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med (1992) 1.68
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (2010) 1.68
Brain tissue sodium is a ticking clock telling time after arterial occlusion in rat focal cerebral ischemia. Stroke (2000) 1.68
beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem (2000) 1.67
Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses (1989) 1.67
High-resolution solution structure of the 18 kDa substrate-binding domain of the mammalian chaperone protein Hsc70. J Mol Biol (1999) 1.66
Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol (2005) 1.65
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol (1998) 1.64
Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant (2008) 1.63
Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood (1991) 1.63
IkappaB is a substrate for a selective pathway of lysosomal proteolysis. Mol Biol Cell (1998) 1.63
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia (2002) 1.62
Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant (2000) 1.62
ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion (2000) 1.61
Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol (1991) 1.61
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med (1994) 1.60
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood (1999) 1.58
Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis (1994) 1.57
Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis (2001) 1.57
Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol (1995) 1.57
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol (1991) 1.55
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res (2000) 1.55
Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant (2006) 1.53
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol (2000) 1.53
Orientational constraints as three-dimensional structural constraints from chemical shift anisotropy: the polypeptide backbone of gramicidin A in a lipid bilayer. Protein Sci (1993) 1.53
Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation (2001) 1.53
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer. Dis Colon Rectum (1994) 1.49
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem (1997) 1.47
Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst (1999) 1.47
Prevalence of HIV antibodies in transsexual and female prostitutes. Am J Public Health (1992) 1.47
Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol (1986) 1.46
Solution structure of P22 transcriptional antitermination N peptide-boxB RNA complex. Nat Struct Biol (1998) 1.45
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood (1995) 1.45
High-dose cytosine arabinoside therapy for refractory leukemia. Blood (1983) 1.44
Spontaneous deletions and duplications of sequences in the genome of cowpox virus. Proc Natl Acad Sci U S A (1984) 1.44
Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J (1998) 1.43